Australian Other Utilities Stock News

Macquarie’s recent conferences and governance update in focus Macquarie Group (ASX:MQG) has stepped up investor engagement, presenting at the Macquarie Asia Conference and planning a session at the Louisiana Energy Conference, while also flagging a proposed constitution amendment for approval at its July AGM. See our latest analysis for Macquarie Group. Macquarie’s recent conference activity and proposed governance changes come as the stock trades at A$236.06, with a 90 day share price return...

Sunrise Energy Metals has appointed globally recognised brand and industrial design expert Peter Arnell as a Non-Executive Director, effective 15 May 2026. By adding a board member credited with reshaping major consumer brands such as Pepsi, Samsung and Reebok, Sunrise is signalling a stronger emphasis on brand-led corporate value creation. We’ll now examine how Arnell’s branding expertise could influence Sunrise Energy Metals’ broader investment narrative and perception among investors. AI...

Why Aroa Biosurgery’s latest earnings matter for ASX:ARX holders Aroa Biosurgery (ASX:ARX) has drawn fresh attention after reporting full year 2026 results, with sales of NZ$103.85 million and a shift from a net loss to a NZ$4.68 million profit. See our latest analysis for Aroa Biosurgery. The latest earnings announcement follows a strong short-term performance, with a 7 day share price return of 13.33% and a 30 day share price return of 21.43%, even though the share price is down 6.85% year...

Botala Energy Limited ( ASX:BTE ) insiders who purchased shares in the last 12 months were richly rewarded last week...

Australian shares are showing resilience, bouncing back from a recent significant downturn, with a modest rise anticipated following encouraging developments on the international stage. In this context, penny stocks—often smaller or newer companies—continue to intrigue investors due to their potential for growth and value. Despite being an outdated term, penny stocks remain relevant as they offer opportunities for those seeking financially strong companies that might be under the radar.

Earlier this week, CellCarta announced it had entered a partnership with Sonic Healthcare USA, naming Sonic as the first commercial laboratory partner in its Lab Network to support commercialization of companion diagnostics across oncology, autoimmune disease and other precision medicine areas. This collaboration links CellCarta’s assay development capabilities with Sonic’s broad clinical lab footprint, potentially deepening Sonic’s role in higher-value precision testing and companion...

Firebird Metals Limited ( ASX:FRB ) insiders who bought shares over the past year were rewarded handsomely last week...

Endeavour Group (ASX:EDV) is restructuring its Pinnacle Drinks business, including a review of its winery footprint and operations. The group plans to sell the Oakridge wine brand and exit or sell other non core winery assets. Winery operations are being consolidated to focus on a tighter set of beverage assets within the Pinnacle portfolio. For investors watching Endeavour Group, this reset follows a period of share price weakness. The stock closed at A$2.86, with the share price down 7.4%...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Even if it's not a huge purchase, we think it was good to see that John Chan, the Non-Executive Chair of Finbar Group...

As Australian shares face a slight retreat, influenced by Wall Street's recent cooling and local inflation concerns, investors are keenly watching how these factors might impact dividend stocks on the ASX. In this environment, identifying robust dividend stocks like Australian Ethical Investment can provide stability and potential income for portfolios amidst market fluctuations.

As Australian shares face a potential retreat, reflecting Wall Street's recent cooling, investors are keenly observing the interplay between local economic indicators and global market trends. In this fluctuating environment, growth companies with substantial insider ownership can be particularly appealing as they often signal confidence from those who know the business best.

Australian shares are set for a slight retreat, influenced by market dynamics both locally and internationally, with Wall Street's recent cooling after hitting new highs. In the context of these fluctuating markets, penny stocks—though an older term—remain relevant as they often represent smaller or newer companies with potential for growth at accessible price points. By focusing on those with strong financial health and solid fundamentals, investors can uncover promising opportunities within...

Electro Optic Systems Holdings has recently raised A$150,000,000 via an institutional placement, A$40,000,000 through a follow-on offering, and plans an additional A$25,000,000 Share Purchase Plan to help fund the acquisition of UK counter-drone and autonomous maritime specialist MARSS, while also adding retired senior Australian Defence leaders Catherine Roberts and Kathryn Toohey to its board. This combination of sizeable equity raising, a defence-focused acquisition, and governance...

Goodman Group (ASX:GMG) has been appointed lead development partner for a proposed data centre campus in Sagamihara City, Kanagawa Prefecture, Japan, highlighting its growing role in digital infrastructure and sustainability focused projects. See our latest analysis for Goodman Group. The Sagamihara announcement comes as Goodman Group trades at A$30.77, with a 30 day share price return of 6.47% and a 90 day share price return of 6.32%. The 3 year total shareholder return of 60.30% contrasts...

Nufarm (ASX:NUF) opened H1 2026 with revenue of A$1.7 billion and basic EPS of A$0.07, alongside net income of A$28.0 million. Over the recent half yearly periods, the company has seen revenue move from A$1.8 billion and EPS of A$0.05 in H1 2025 to A$1.6 billion with EPS declining to A$0.54 in H2 2025, before landing at the latest H1 2026 levels. This gives investors a clearer read on how margins are tracking quarter to quarter. Against a backdrop of trailing twelve month losses and analyst...

Income investors are being pulled in several directions by stubborn inflation signals, shifting rate expectations and uneven consumer data across major economies. In this kind of cross‑current, high yield alone is not enough; durability matters just as much as payout. That is exactly what the Dividend Fortresses screener is built to target, focusing on stocks with dividend yields of 5% or more that aim to hold up when conditions get choppy. In this article, you will see three stocks from that...

Fresh from its H1 2026 update, Select Harvests (ASX:SHV) is under the spotlight as you weigh recent revenue and EPS trends against the stock’s A$3.90 share price and what they might signal for profitability. The company has seen half year revenue shift from A$226.4 million in H2 2024 to A$293.8 million in H2 2025, while basic EPS over the same periods moved from A$0.03 to A$0.02, setting up a mixed read on earnings momentum. With trailing 12 month net profit margin at 8.4% versus 8.7% in the...

archTIS Limited ( ASX:AR9 ), might not be a large cap stock, but it led the ASX gainers with a relatively large price...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Insiders who bought Recce Pharmaceuticals Ltd ( ASX:RCE ) stock in the last 12 months were richly rewarded last week...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Australian shares are poised for a slight retreat, influenced by Wall Street's recent cooling and ongoing global economic discussions. Despite the fluctuating market conditions, penny stocks—often overlooked due to their smaller size or newer status—can still present valuable opportunities when backed by solid financials. In this article, we explore several promising Australian penny stocks that combine financial strength with potential for long-term growth.

Earlier in May 2026, Telix Pharmaceuticals reported that its Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblastoma completed enrolment, with no dose-limiting toxicities observed so far at doses up to 10GBq alongside standard-of-care therapy. This progress, together with ongoing Phase 3 evaluation of TLX101-Tx as the first radiopharmaceutical therapy to reach this stage in glioblastoma, highlights Telix’s attempt to build a differentiated neuro-oncology franchise using...